Boston Scientific Corporation develops, manufactures, and markets medical devices for interventional medical specialties worldwide. It operates in two segments: MedSurg and Cardiovascular. The company offers devices for gastrointestinal, urological, neurological, and cardiac conditions, including products for diagnosis, treatment, and monitoring. Incorporated in 1979, it is headquartered in Marlborough, Massachusetts.
Cyberattack cuts guidance, Penumbra deal offsets, competition and recalls weigh
▼
Cyberattack forces guidance cut The August cyberattack disrupted manufacturing and shipping, so BSX now expects to miss its 2026 sales and profit targets. The full cost is unknown, and the updated outlook comes October 28. This uncertainty pushes the stock down because investors can't yet measure the damage.
This is the main new negative event that directly caused the guidance cut and stock drop.
▼
Weak WATCHMAN and EP businesses lower 2026 outlook BSX cut its 2026 growth and earnings outlook because its WATCHMAN heart implant and electrophysiology businesses are weak. Management expects pressure into 2027, with growth below the market rate. This lowers near-term profit expectations and weighs on the stock.
This explains the fundamental business weakness behind the lowered guidance, separate from the cyberattack.
▲
Penumbra acquisition expands clot-removal business BSX agreed to buy Penumbra for $14.5 billion, adding blood-clot removal technology to its heart division. The deal will slightly reduce earnings per share at first (6-8 cents) but is expected to improve later. It signals long-term growth and supports the stock.
This is a major new strategic move that offsets some negative sentiment and shows future growth potential.
▼
Citi downgrade and new competition Citi downgraded BSX to Neutral, warning of rising competition in heart procedures and expected market-share loss to Abbott's Amulet device in 2027. New proposed guidelines could also hurt WATCHMAN sales. This adds pressure on the stock as investors worry about future growth.
This is a fresh analyst downgrade highlighting competitive and regulatory risks that directly affect BSX's valuation.
Q3 2026
▼3▲1
BSX hit by guidance cuts, cyberattack, recalls despite pipeline bets
▼
Guidance cut twice on WATCHMAN weakness and lost EP share Boston Scientific lowered its 2026 profit outlook twice, first because its WATCHMAN heart implant sold poorly and it lost share in electrophysiology, then again after an August cyberattack disrupted orders and shipping.
Repeated guidance cuts are the main negative force that pushed the stock down during the quarter.
▼
August cyberattack disrupted orders and shipping A cyberattack in August forced another guidance cut, with the company unable to say how much the disruption would cost. Orders and shipping were affected, hurting sales in the quarter.
This was a new, unexpected operational shock that directly hurt results and investor confidence.
▼
Recalls and Citi downgrade on rising competition Multiple product recalls, including a serious Class I recall of the ENROUTE device, raised regulatory and reputational concerns. Citi downgraded the stock to Neutral, expecting Boston Scientific to lose more share to Abbott's Amulet in 2027.
These events added regulatory and competitive pressure that weighed on the stock.
▲
Pipeline investments and Penumbra acquisition support long-term growth Boston Scientific invested $1.5B in MiRus, secured a $3B TAVR option, and agreed to buy Penumbra for $14.5B to expand clot-removal technology. These bets slightly dilute near-term earnings but aim to strengthen future growth.
These are the main positive strategic moves that could offset current troubles over the long run.
News & notes movingBSX
United States
BSX▲
Boston Scientific wins up to $135.7M U.S. defense health contract
Boston Scientific has won a maximum $135.7M indefinite-delivery, indefinite-quantity contract for cardiovascular procedural packages and ancillary items. The five-year contract carries no option periods, with the ordering period running through September 29, 2031. The products will support the U.S. Army, Navy, and Air Force, funded by fiscal 2026–2031 Defense Working Capital Funds. The Defense Logistics Agency Troop Support is the contracting activity.
BSX · Demand · Positive Boston Scientific won a $135.7M U.S. defense health contract for cardiovascular procedural packages supporting Army, Navy, and Air Force.
Wells Fargo Estimates $300 Million Cyber Hit to Boston Scientific Q3 Sales
Wells Fargo estimates Boston Scientific's August cybersecurity incident will cost roughly $300 million in third-quarter sales and about $0.13 per share in earnings. Analyst Larry Biegelsen lowered the firm's price target on Boston Scientific to $48 from $50 on September 24 while maintaining an Equal Weight rating, and cut fiscal Q3 estimates to reflect eight days of operational downtime. Boston Scientific disclosed unauthorized activity on certain systems on August 25 that caused a network outage affecting manufacturing and order processing, and said the incident was likely to materially impact its third-quarter and full-year 2026 results. The company reported on September 9 that manufacturing, order fulfillment, and shipping were fully restored, and it now expects full-year 2026 net sales growth of approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent organically, with adjusted EPS of $3.28 to $3.32. Wells Fargo left its growth estimates for 2027 and beyond unchanged, and Boston Scientific plans to provide an updated operational and financial outlook when it reports third-quarter results on October 28.
BSX · Capital · Negative Wells Fargo cut its price target to $48 and slashed Q3 estimates on a ~$300M sales and ~$0.13 EPS hit from the August cyber incident.
Boston Scientific Recalls 982 StoneSmart Connect Power Adapters
Boston Scientific has initiated a Class II recall of its StoneSmart Connect Console power adapters, affecting 982 units distributed across the US and multiple international markets. The recall comes as the company's shares have eased 1.7% over the last trading day and are down 6.2% over the past month, with a 1-year total shareholder return down 54.7%. Boston Scientific closed at $43.92, well below a widely followed fair value narrative of $61.07 that implies 28% undervaluation. The company is pursuing a restructuring program targeting about US$500m in annual run rate savings exiting 2029, alongside a US$2b share repurchase completed in Q2 2026, even as near-term guidance reflects WATCHMAN, EP and cyberattack related pressure. The bull case could crack if Electrophysiology and WATCHMAN weakness lingers longer than analysts assume or if the Penumbra deal proves harder to integrate.
BSX · Regulation · Negative Boston Scientific initiated a Class II recall of 982 StoneSmart Connect Console power adapters across US and international markets.
BSX · Capital · Positive Company is pursuing a restructuring program targeting about US$500m in annual run-rate savings exiting 2029 and completed a US$2b share repurchase in Q2 2026.
Boston Scientific Eyes 2027-2028 Launch Wave as EP Growth Set to Stall
Boston Scientific is preparing a steady stream of product launches over the next two years that it expects to become an important source of incremental growth. In Interventional Cardiology, the company plans to launch the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter in the first half of 2027, following FRACTURE trial data presented as a late-breaker at EuroPCR in May that met all endpoints. In Endoscopy, Boston Scientific has received FDA clearance for RIVOS, a first-of-its-kind single device designed to consolidate multiple exchanges and streamline endoscopic ultrasound biliary drainage, while advancing enrollment in the THRIVE trial of the TIVUS Ultrasound System for renal denervation, a technology acquired through the SoniVie Ltd. acquisition that management still expects to reach the market in 2028. Within Cardiac Rhythm Management, the company faces competitive pressure and portfolio gaps it expects to address with PRECEDENT, its new defibrillation platform scheduled to launch in the second half of 2027. In Electrophysiology, where FARAPULSE has driven a faster-than-anticipated transition to pulsed-field ablation and U.S. PFA revenues now account for approximately 80% of the atrial fibrillation market, Boston Scientific now expects global EP growth to emerge flat in the second half of 2026, with the U.S. EP business expected to regain momentum in the second half of 2027 on the launch of FARAWAVE Ultra and its entry into the intracardiac echocardiography market, and further improvement forecast for 2028 with FARAFLEX. Among peers, Abbott announced its Volt PFS system was used for the first time in Canada at the McGill University Health Centre in Montreal to treat AFib patients after receiving Health Canada authorization in April 2026, and Globus Medical secured CE Mark for Excelsius3D, its intelligent mobile imaging platform that combines 3D cone-beam computed tomography, 2D fluoroscopy and digital radiography in a single system. Over the past 12 months, Boston Scientific shares have dropped 55.4% compared with the industry's 29.7% decline, and the stock currently carries a Zacks Rank #5 (Strong Sell).
BSX · Competition · Negative Boston Scientific expects global EP growth to be flat in H2 2026 amid competitive pressure and portfolio gaps in CRM.
BSX · Technology · Positive Boston Scientific detailed a 2027-2028 launch wave including SEISMIQ 4CE, FDA-cleared RIVOS, PRECEDENT, and FARAWAVE Ultra/FARAFLEX.
ABT · Competition · Neutral Abbott's Volt PFS was used for the first time in Canada after Health Canada authorization, a competitive PFA milestone mentioned alongside Boston Scientific's EP franchise.
Zacks Adds AGCO, Aegon and Boston Scientific to Strong Sell List
Zacks Investment Research added AGCO Corporation, Aegon Ltd. and Boston Scientific Corporation to its Zacks Rank #5 Strong Sell List on September 21st. AGCO, an agricultural equipment manufacturer, saw its Zacks Consensus Estimate for current-year earnings revised 9.3% downward over the last 60 days. Aegon, an insurance, pensions and asset management services company, had its current-year earnings estimate revised 10.1% downward over the same period. Boston Scientific, a medical devices company, saw its current-year earnings estimate revised 2.1% downward over the last 60 days.
GE Aerospace to Acquire Consolidated Precision Products for About $11.7 Billion
GE Aerospace announced it is acquiring private precision-manufacturing company Consolidated Precision Products for about $11.7 billion, a deal that values the target at roughly 26 times EBITDA. Consolidated Precision Products is one of four major component manufacturers in the industry, building jet turbine blades and airfoils, and has worked with GE for more than 15 years as perhaps its third-largest supplier in that group. Management claims the deal will be accretive to earnings per share in year one, funded with about $7 billion in cash from the balance sheet plus new debt, though the transaction is expected to lever up the balance sheet. The move is a vertical-integration play that should give GE priority on procurement and faster ramp-up on new engine designs, and it sent shares of rival supplier Howmet down 7% to 8% on the news. The podcast also discussed Boston Scientific's disclosure that a cyberattack will prevent it from meeting quarterly and annual sales targets, and a mailbag question on reverse stock splits.
Citi Downgrades Boston Scientific to Neutral on Competition and Cyberattack Fallout
Citi downgraded Boston Scientific to Neutral from Buy, citing the lingering aftermath of an August cyberattack and rising competition across several of its businesses. The bank cut its price target on the medical device maker to $50 from $57, implying roughly 14% upside based on the Sept. 16 close. Analyst Joanne Wuensch said Boston Scientific has been hurt this year by a more mature U.S. pulsed field ablation market with increased competition, a stagnating left atrial appendage closure market, Urology hiccups, and the cybersecurity attack, and she has revised her estimates down eight times year to date. Wuensch warned that new proposed guidelines from the Heart Rhythm Society could weigh on sales of the company's key Watchman LAAC device, projecting Watchman sales will fall 7.6% in the second half of the year followed by an 8.8% drop in 2027, and said Boston Scientific is likely to lose market share when Abbott Laboratories' Amulet LAAC launches in 2027. She added that while she is confident the company will work through its problems, the time to resolution is opaque, investor patience has run thin, and the recovery path remains unclear.
BSX · Competition · Negative Citi downgraded Boston Scientific to Neutral, citing rising competition in pulsed field ablation and LAAC plus expected share loss to Abbott's Amulet.
BSX · Regulation · Negative New proposed Heart Rhythm Society guidelines could weigh on sales of Boston Scientific's key Watchman LAAC device.
ABT · Competition · Positive Citi expects Boston Scientific to lose LAAC market share when Abbott's Amulet device launches in 2027, a competitive gain for Abbott.
Boston Scientific Recalls LUX-Dx Cardiac Monitor Over Delayed AF Alerts
Boston Scientific has initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System and software over delays in atrial fibrillation Burden Alerts. The recall targets multiple versions of LUX-Dx hardware and associated software that may postpone detection alerts for atrial arrhythmias used in patient monitoring, and the US FDA has taken enforcement interest in the action. Boston Scientific is a US-based medical equipment group with a market cap of about $63.6b that builds devices used in interventional procedures across cardiology and other specialties. The company said the LUX-Dx software recall leans directly into regulatory and product lifecycle risk already flagged in its narrative, alongside earlier device recalls and the ACURATE valve discontinuation, and puts more weight on the risk that continual product refresh and acquisition integration can introduce operational setbacks. The key question for investors is whether the LUX-Dx issues stay contained within a niche cardiac monitoring segment or start to cloud physician confidence and hospital purchasing decisions across cardiology, where Boston Scientific is working to support growth and margins.
BSX · Regulation · Negative Boston Scientific initiated a voluntary global recall of its LUX-Dx cardiac monitor over delayed AF alerts, drawing FDA enforcement interest and adding regulatory/product-lifecycle risk.
Boston Scientific to Buy Penumbra for $14.5 Billion in Thrombectomy Push
Boston Scientific has agreed to acquire Penumbra for $14.5 billion, a deal that would expand the company's presence in thrombectomy, the market for removing blood clots and blockages from blood vessels. The transaction is expected to close in the second half of 2026, subject to customary closing conditions including regulatory clearances, and will be integrated into Boston Scientific's Cardiovascular division. The company said the deal is expected to weigh on adjusted earnings per share by 6-8 cents in the first full year after closing, with the earnings impact improving thereafter. Earlier this year Boston Scientific acquired Valencia Technologies, adding the eCoin system to its Urology portfolio and expanding into implantable tibial nerve stimulation, a deal expected to have an immaterial impact on adjusted earnings per share in 2026 though more dilutive to GAAP earnings. The company also acquired full ownership of Nalu Medical, paying approximately $523 million upfront for the remaining stake, net of cash acquired, after holding an equity stake of approximately 9% since 2017, with the business integrated into the Neuromodulation division. In 2025, closed acquisitions added 340 basis points to sales, contributing to 15.8% organic revenue growth, while the additions of Bolt Medical and SoniVie advanced its coronary and peripheral disease and interventional cardiology strategies.
Biotech & Genomic Medicine › Cardiovascular & Heart-Failure Therapeutics Competition
BSX · Capital · Positive Boston Scientific agreed to acquire Penumbra for $14.5 billion, expanding its thrombectomy presence in its Cardiovascular division.
PEN · Capital · Positive Penumbra is being acquired by Boston Scientific for $14.5 billion, a takeover of the company.
Boston Scientific Warns Cyberattack Will Break 2026 Guidance
Boston Scientific Corporation disclosed that an August 25 cyberattack disrupted manufacturing and shipping, making it unlikely to meet its previously issued third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share. The company said operations have since resumed, but the incident is still expected to weigh on third-quarter and full-year results. The disruption did not stem from a product-quality problem; the lost sales were orders that could not ship, and distribution is already back online. Farapulse, Boston Scientific's pulsed-field-ablation system, still commands a major share of the US atrial-fibrillation market, though the company had already projected flat global electrophysiology growth for the second half of 2026 after lowering its market-share assumptions. Hedge fund holdings in BSX slipped to 99 in the second quarter of 2026 from 106 in the prior quarter, while short interest remains low at 1.9% of the float.
Novartis and Boston Scientific Slide, Intel Prices Rise
Novartis shares fell after its third clinical-trial setback in a week, as a treatment for a rare muscle-wasting disease failed a late-stage study. Boston Scientific also declined, saying a cybersecurity incident has disrupted product shipments and will cause it to miss its sales growth and earnings estimates for the year. Meanwhile, Intel rose on a report that it may raise computer chip prices next month.
Boston Scientific Cuts 2026 Outlook Amid Market Weakness
Boston Scientific has lowered its 2026 expectations, now calling for organic revenue growth of 5% to 6% and adjusted earnings per share of $3.28 to $3.32, or 7% to 8% growth, as weakness in its WATCHMAN and Electrophysiology businesses weighs on performance. Management expects the pressure to extend into 2027, with revenue growth potentially remaining below its weighted average market growth rate and adjusted EPS growth limited. However, growth could pick up meaningfully in 2028, driven by seven new launches that collectively address a total addressable market of nearly $25 billion, including the SEISMIQ 4CE Coronary IVL Catheter and the FARAWAVE Ultra mapping and ablation catheter, as well as the pending Penumbra acquisition. The company is also pursuing a restructuring program targeting approximately $500 million in annual run-rate savings by the end of 2029, with more than half expected by the end of 2027, to support operating-margin expansion and stronger adjusted EPS growth in 2028 and beyond.
Roivant Sciences Surges 24% on Positive Trial Results
Roivant Sciences shares rallied 24% after the pharma company reported positive Phase 2 trial results for its subsidiary Pulmovant's mosliciguat, which showed a clinically meaningful and statistically significant reduction in pulmonary vascular resistance in patients with pulmonary hypertension and interstitial lung disease. Meanwhile, Lockheed Martin edged up 0.7% after UBS upgraded the stock to buy, citing underappreciated earnings growth potential. Novartis tumbled 12% after its del-desiran drug failed to show significant improvement in a Phase 3 trial for myotonic dystrophy type 1. Peloton Interactive slid more than 4% following a Morgan Stanley downgrade to underweight, citing structural headwinds in fitness. Boston Scientific slipped over 2% after warning that a recent cyberattack likely impacted its 2026 sales and profit targets. Bloom Energy rose over 6% as it prepares to join the S&P 500 on Sept. 21, having gained about 190% this year on the AI data center buildout.
Boston Scientific Restores Shipping After Cyberattack
Boston Scientific has begun restoring shipping capabilities for most of its products across its major distribution centers worldwide following a recent cybersecurity incident, causing its shares to trade higher on Friday. The Marlborough, Massachusetts-based medical device maker had disclosed last week that the incident disrupted its worldwide operations. With assistance from CrowdStrike and other experts, Boston Scientific said it is increasingly confident that unauthorized access was limited to some internal-facing IT infrastructure. The company noted it will take time to clear the current backlog as it progressively moves customer orders through the fulfillment process. TD Cowen analyst Joshua Jennings, who has a Buy rating and a $56 price target, called the update a big step forward, adding that the stock reaction fails to reflect the progress.
Boston Scientific Issues Multiple Worldwide Product Recalls
Boston Scientific has initiated multiple worldwide product recalls, including a Class I recall of its ENROUTE Transcarotid Neuroprotection System due to risks of arterial sheath tip separation, and Class II recalls of certain OverStitch Suture Cinch endoscopic devices citing deployment and suture cutting failures. The Class I recall affects 164,687 neuroprotection units across two product versions, while the Class II recalls cover 60,654 standard units plus additional long versions. These products are distributed worldwide and are used in high-acuity procedures, so the field actions could disrupt physician workflows and reorder patterns. The recalls add operational, regulatory, and reputational pressures for Boston Scientific in 2026, and investors will watch for the company's formal update on recall-related costs, remediation timing, and any sales or margin impact in its next earnings report.
Intuitive Surgical's Record Cash Flow Fuels Innovation Advantage
Intuitive Surgical's surging cash generation is giving it a meaningful competitive edge as the robotic surgery leader doubles down on innovation. First-half 2026 free cash flow jumped 71% year over year to $1.8 billion, while cash and investments reached $8.6 billion, providing ample financial flexibility to fund research, manufacturing expansion and shareholder returns without compromising growth initiatives. Management is using that financial strength to widen its technology moat, intentionally growing R&D faster than SG&A, expanding manufacturing capacity, and rolling out more than 100 planned updates for the da Vinci 5 platform. The company is also advancing next-generation programs, including a flexible robotic GI endoscope, while supporting innovation across AI, robotics, imaging and advanced materials. Alongside these investments, ISRG repurchased $379 million of stock during the quarter, underscoring confidence in its long-term outlook. Among peers, Boston Scientific delivered another solid quarter with second-quarter 2026 revenues rising 7.5% to $5.44 billion and adjusted EPS climbing 15% to 86 cents, though management trimmed its full-year outlook due to WATCHMAN and electrophysiology pressures. Medtronic secured an expanded CE Mark for the Affera Mapping and Ablation System with the Sphere-9 catheter to treat ventricular arrhythmias, making it the first all-in-one mapping and ablation, dual-energy catheter approved in Europe for ventricular ablation, and also received FDA Breakthrough Device Designation for the technology. ISRG shares have lost 34.6% year-to-date compared with the industry's decline of 6.9%, and the Zacks Consensus Estimate for 2026 earnings implies a 20.3% improvement from the year-ago period.
Robotics & Physical AI › Surgical & Medical Robotics ▲Capital
ISRG · Capital · Positive Record free cash flow and $379M buyback highlight financial strength and shareholder returns.
ISRG · Technology · Positive R&D investment and da Vinci 5 updates plus next-gen programs widen technology moat.
MDT · Technology · Positive Expanded CE Mark and FDA Breakthrough Device Designation for Affera system are positive regulatory and product advancements.
BSX · Demand · Neutral Boston Scientific's Q2 revenue and EPS growth are positive, but trimmed full-year outlook due to WATCHMAN and EP pressures creates mixed impact.
Boston Scientific cyberattack causes global disruption
Boston Scientific, a U.S. medical device maker, disclosed in a federal filing that a cyberattack is causing an ongoing global disruption to its operations, affecting its ability to ship and process orders. The company, which treats around 48 million patients a year, said the attack began on Tuesday and has limited access to its IT systems and business applications. Boston Scientific has not commented on whether patients are affected or provided a timeline for restoring systems. The company is the latest healthtech firm to be hacked this year, following incidents at Abbott Laboratories, Medtronic, and Stryker.
Midday movers: Abercrombie surges, Intuit slides on weak guidance
Abercrombie & Fitch soared 37% after trouncing fiscal second-quarter estimates and raising its full-year outlook, with adjusted earnings of $2.42 per share and revenue up 5% to $1.27 billion, helped by tariff refunds and stronger growth at its Abercrombie unit. Intuit fell 4% after offering disappointing fiscal year 2027 guidance of $23.3 billion to $23.5 billion in revenue, below the $23.7 billion analyst estimate, though its fiscal fourth-quarter earnings and revenue beat expectations. Meta Platforms jumped 3% after reaching a settlement with state attorneys general in a case alleging it made its apps addictive to teenagers. Zoom Communications dropped 7% after its third-quarter forecast of $1.46 to $1.48 earnings per share missed the $1.50 estimate. Kohl's rose 2% after raising its full-year outlook, partly due to $150 million in tariff refunds, and announced share buybacks of up to $100 million in 2026. J.M. Smucker climbed 3% on fiscal first-quarter revenue of $2.22 billion, topping the $2.13 billion consensus. SolarEdge Technologies jumped nearly 8% after a UBS upgrade to buy, citing an FCC policy expected to boost market share and pricing power. Semtech rose over 8% on second-quarter earnings beat, with adjusted EPS of 71 cents versus 61 cents expected. Boston Scientific fell 5% after reporting a cybersecurity incident causing product disruptions. SAP declined 3% after a UBS downgrade to neutral, citing slow delivery of agentic AI.
Atrial Fibrillation Device Market to Reach $29B by 2035
The global atrial fibrillation treatment devices market is projected to grow from USD 9.6 billion in 2026 to USD 29.0 billion by 2035, at a compound annual growth rate of 13.1%, according to a new report from ResearchAndMarkets.com. The market expansion is driven by the rising prevalence of atrial fibrillation, an aging population, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Ablation catheters are expected to account for approximately 75% of market revenue, while the left atrial appendage closure segment is projected to grow at a CAGR of 13.4%, the fastest among device types. Pulsed field ablation is forecast to generate more than 60% of total market revenue by 2035. North America is projected to retain close to 50% of global revenue, while Asia-Pacific is expected to register the fastest regional growth. Key players include Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic.
U.S. Futures Flat Ahead of Inflation Data and Nvidia Results
U.S. stock futures hovered around the flatline on Wednesday as investors awaited the latest inflation data and Nvidia's quarterly results. Among premarket movers, Intuit tumbled 11.8% to $315.30 after issuing fiscal 2027 guidance that fell well short of expectations, overshadowing a strong fourth-quarter earnings beat. Semtech surged 4.7% after reporting record fiscal second-quarter results, with revenue of $341.9 million and adjusted EPS of $0.71 beating estimates, and data-center revenue hitting a record $100 million. SolarEdge rose 5.6% after UBS upgraded it to Buy, citing the FCC's decision to add foreign-produced power inverters to its national-security Covered List, which could tighten supply and benefit domestic suppliers. Spyre Therapeutics fell 11.7% after deciding not to develop its drug SPY072 as a standalone rheumatoid arthritis treatment despite positive statistical results, while Boston Scientific dropped 3.2% on a cybersecurity incident disrupting operations.
Intuit, Zoom, Kohl's Lead Premarket Declines; SolarEdge, Semtech Rise
Intuit shares plunged 11% in premarket trading after the financial technology platform issued fiscal 2027 revenue guidance of $23.279 billion to $23.512 billion, below the $23.7 billion analysts expected, though its fiscal fourth-quarter earnings and revenue beat estimates. The disappointing outlook dragged other software stocks lower, with the iShares Expanded Tech-Software ETF down over 1%, ServiceNow off more than 2.5%, and Workday and Salesforce each down 2%. Zoom Communications fell 7% after its third-quarter earnings per share guidance of $1.46 to $1.48 came in short of the $1.50 FactSet consensus. Kohl's declined 5% after reporting a 0.9% drop in second-quarter comparable sales, worse than the 0.6% decline expected, but the retailer raised its full-year outlook, partly due to $150 million in tariff refunds, and restarted share buybacks of up to $100 million in 2026. On the upside, J.M. Smucker climbed 5.6% after fiscal first-quarter revenue of $2.22 billion topped the LSEG consensus of $2.13 billion, SolarEdge jumped nearly 7% following a UBS upgrade to buy on a new FCC policy, and Semtech rose more than 5% after beating earnings estimates with adjusted EPS of 71 cents versus 61 cents expected. Box gained over 2% on revenue beat, while Boston Scientific fell more than 3% after disclosing a cybersecurity incident causing product disruptions, and SAP dropped almost 4% after a UBS downgrade to neutral on slow agentic AI delivery.
Boston Scientific Stock Tests Historical Support as Growth Outlook Weakens
Boston Scientific shares have fallen back to a price zone between $46.56 and $51.46 that has acted as support on six prior occasions, now trading around $49.01. The company has cut its full-year 2026 adjusted EPS guidance to a range of $3.28 to $3.32, citing a sharp slowdown in its U.S. WATCHMAN heart device market and unexpected competitive share losses in its Electrophysiology business. Management now expects limited adjusted EPS growth in 2027 and is guiding for global WATCHMAN revenue to decline mid- to high-single digits year-over-year in the second half of 2026. Excluding a multi-year advance that began in late 2023, prior defenses of this support level produced a median peak gain of 8.6% over holding periods of 11 to 47 days.
Boston Scientific completes multi-year buyback of 39.9 million shares
Boston Scientific has completed a multi-year share repurchase program, buying back 39,922,436 shares for about US$2.0 billion, representing 2.69% of the company's shares. The completed buyback provides an additional data point on how Boston Scientific is allocating capital and managing its share count. At the latest share price of US$51.83, the stock has seen a 20.42% one-month return, although the year-to-date return is down 45.28% and the one-year total shareholder return has fallen 49.76%. On the most followed valuation view, Boston Scientific's fair value of $72.25 sits well above the recent share price, suggesting the stock is 28.3% undervalued. Investors also need to watch for risks around tariff-related cost headwinds and ongoing competitive and regulatory pressure on products like WATCHMAN.
Boston Scientific Hurt by Weak Q2 Results and Guidance Cut
Boston Scientific Corporation shares fell after its second-quarter results and CHAMPION-AF data release, according to TCW Concentrated Large Cap Growth Fund's Q2 2026 investor letter. The fund said results modestly beat expectations, but U.S. Electrophysiology and Watchman franchises missed consensus, and management lowered 2026 organic sales growth guidance to 10-11%. The CHAMPION-AF data released at the end of March hit all endpoints but failed to act as a positive catalyst for the stock. The fund believes current valuation may have overly discounted the company's long-term earnings growth profile, and shares remain under review. Boston Scientific closed at $51.42 per share on August 12, 2026, with a one-month return of 15.24% and a 52-week loss of 50.63%.
Boston Scientific CEO Mahoney buys over 200,000 shares for $10 million
Boston Scientific Chairman, President and CEO Michael F. Mahoney purchased 208,359 shares of the company's common stock for a total transaction value of $10.1 million, according to an SEC filing. The purchase, executed on August 3, 2026, at a weighted average price of $48.34 per share, expands Mahoney's total equity interest by 13% to approximately 1.6 million shares valued at $78.08 million based on that day's close. The acquisition was made through multiple trades at prices ranging from $47.87 to $48.47, with most shares bought directly and about 22,000 shares acquired through a discretionary rebalancing within the company's 401(k) Retirement Savings Plan. The transaction follows a period of negative price momentum, with Boston Scientific recording a -54% return over the prior 12 months, and comes after management twice cut revenue guidance in 2026 due to a competitive marketplace. The company, which has a market capitalization of $73 billion and trailing twelve-month revenue of $21 billion, is looking to a brighter future with a robust pipeline of new products expected from 2027 through 2029 and a restructuring aimed at cutting $500 million in costs.
Boston Scientific Recalls Cardiac Ablation Generators and Vascular Sheaths
Boston Scientific has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air embolism risks. The recalls affect a broad mix of devices used in cardiac and vascular procedures across several international markets, with the FARADRIVE sheath recalls involving more than 700,000 units across US, global, and IDE use. The PFA generator issues mainly involve labeling and smaller unit counts, while the Rapid Refill system recall brings in a third-party component issue. Regulators and hospitals are assessing the implications for device safety protocols, clinical workflows, and future use of the impacted products.
Boston Scientific Cuts 2026 Guidance on Slower WATCHMAN Demand and Electrophysiology Share Losses
Boston Scientific lowered its 2026 sales and earnings outlook, citing slower WATCHMAN demand, U.S. electrophysiology share losses, and limited operating leverage. The company now expects reported sales growth of 5.5 to 6.5 percent, down from a prior range of 7 to 8.5 percent, while organic sales growth guidance fell to 5 to 6 percent from 6.5 to 8 percent. Adjusted earnings per share are now seen at $3.28 to $3.32, below the previous $3.34 to $3.41. The third-quarter outlook also points to a sharper slowdown, with reported and organic sales growth of 3 to 5 percent and adjusted earnings of 80 to 82 cents per share, below the Zacks Consensus Estimate of 84 cents. Management expects lower WATCHMAN and electrophysiology sales to weaken product mix and push full-year adjusted gross margin below the 2025 level, while adjusted operating margin expansion is now forecast at 0 to 25 basis points, down from 50 to 75 basis points. Key recovery catalysts, including FARAWAVE Ultra and intracardiac echocardiography products, are not expected until the second half of 2027, leaving the company exposed to rivals such as Abbott Laboratories, which reaffirmed 6.5 to 7.5 percent comparable sales growth guidance for 2026. A restructuring program targeting about $500 million in run-rate savings exiting 2029 is expected to deliver more than half of the savings and related spending by the end of 2027, but near-term revenue growth is forecast below the weighted average market growth rate with limited adjusted earnings growth in 2027. Shares of Boston Scientific have gained 3.7 percent since the second-quarter earnings announcement, outperforming the industry's 1.5 percent decline, though the stock currently carries a Zacks Rank of 5, or Strong Sell.
Bristol-Myers Raises Full-Year Outlook as Cancer Drugs Drive Q2 Beat
Bristol-Myers Squibb lifted its full-year outlook after reporting better-than-expected second-quarter 2026 results driven by higher sales of its cancer therapies. The company posted approximately $13.0 billion in revenue, beating consensus by $1.23 billion, with its growth portfolio contributing $7.6 billion. Adjusted earnings per share rose about 40% year-over-year to $2.04, exceeding estimates by $0.44. Bristol-Myers now expects full-year revenue of about $49.0 billion to $50.0 billion and adjusted EPS of $6.75 to $7.00, up from prior guidance and ahead of consensus. In other healthcare news, Johnson & Johnson agreed to pay up to $5.5 billion to settle remaining talc lawsuits alleging its products caused ovarian cancer, conditioned on at least 95% participation by claimants. Curium is in advanced talks to acquire Lantheus Holdings for about $7 billion upfront, with an additional $12.50 per share in contingent value rights, potentially valuing the deal at $8 billion. Boston Scientific shares slipped after its full-year outlook trailed consensus, despite second-quarter revenue of $5.4 billion beating estimates. Most Medicare Part D enrollees will face higher premiums in 2027 after the Trump administration ended a subsidy program, with three out of four seeing increases. The S&P 500 Health Care Index Sector edged up 0.12% during the week.
Eight of nine healthcare companies beat EPS estimates this week
Eight out of nine healthcare companies that reported quarterly results this week beat earnings-per-share expectations, while all nine exceeded revenue consensus. Centene posted second-quarter revenue of $53.6 billion, topping estimates by $6.1 billion, and raised its full-year revenue guidance to $193.5 billion to $197.5 billion. Boston Scientific reported revenue of $5.4 billion, beating by $70 million, but lowered its full-year net sales growth outlook to 5.5% to 6.5% year-over-year. DexCom beat on both top and bottom lines and raised the midpoint of its 2026 revenue guidance to a range of $5.18 billion to $5.25 billion. Universal Health Services was the only company to miss EPS estimates.
Boston Scientific Lowers Outlook as WATCHMAN and Electrophysiology Slowdowns Weigh on Growth
Boston Scientific reported second-quarter revenue of $5.44 billion, beating analyst estimates of $5.36 billion, but issued third-quarter revenue guidance of $5.27 billion that fell short of the $5.39 billion consensus. The company lowered its full-year adjusted earnings per share guidance to $3.30, a 2.2% reduction, citing unexpected slowdowns in its WATCHMAN left atrial appendage closure device and U.S. Electrophysiology business. CEO Michael Mahoney pointed to rapid shifts in clinical adoption and competitive pressures, particularly from pulsed-field ablation devices, as factors that will likely persist into 2027. A new restructuring program targeting $500 million in run-rate savings by 2029 was announced, with meaningful margin expansion not expected until 2028. Management highlighted seven major product launches planned for 2028 and beyond as key catalysts for a return to higher growth.
BSX · Demand · Negative Unexpected slowdowns in WATCHMAN and Electrophysiology, with competitive pressures from pulsed-field ablation devices, led to lowered guidance.
Penumbra reports Q2 2026 GAAP EPS of $0.88 on revenue of $390M
Penumbra reported second-quarter 2026 financial results with GAAP earnings per share of $0.88 and total revenue of $390 million. Global thrombectomy revenue reached $259.0 million, a 12.5% increase from the second quarter of 2025, while global embolization and access revenue rose 20.0% to $131.1 million. Gross profit margin improved to 67.9%, up 1.9 percentage points year-over-year. Total operating expenses were $223.9 million, including $25.4 million in research and development and $198.5 million in selling, general and administrative costs, which contained $6.9 million in acquisition-related expenses tied to the pending acquisition of Penumbra by Boston Scientific Corporation. Income from operations was $41.0 million and net income was $34.8 million.
PEN · Capital · Positive Penumbra reported Q2 GAAP EPS of $0.88 on revenue of $390M, with revenue growth in both thrombectomy and embolization segments and improved gross margin.
BSX · Capital · Positive Penumbra's strong Q2 results and improved margins support the pending acquisition by Boston Scientific, making the deal more attractive.
Boston Scientific shares rise 7.1% after Q2 beat, recall, and restructuring plan
Boston Scientific shares climbed 7.1% after the company reported second-quarter 2026 sales of US$5,442 million and net income of US$907 million, while also issuing a recall of its Rapid Refill Continuous Injection System and launching a multi-year global restructuring plan. The restructuring program is expected to cost up to US$800 million and aims to deliver approximately US$500 million in annual pre-tax expense reductions by 2029. The company raised its full-year 2026 net sales growth outlook to roughly 5.5% to 6.5%. The restructuring is designed to protect profitability amid pressures in electrophysiology and left atrial appendage closure, potentially freeing resources for reinvestment in higher-growth areas like FARAPULSE and WATCHMAN.
Boston Scientific Q2 revenue rises 7.5% to $5.44 billion, beating estimates
Boston Scientific reported second-quarter revenue of $5.44 billion, a 7.5% increase from the same period last year, surpassing the Zacks Consensus Estimate of $5.38 billion. Earnings per share came in at $0.86, compared to $0.75 a year ago and above the consensus estimate of $0.83. U.S. revenue reached $3.43 billion, while rest-of-world revenue was $2.02 billion, both exceeding analyst projections. Within its segments, cardiovascular worldwide net sales grew 8.3% to $3.62 billion, and MedSurg worldwide net sales rose 5.9% to $1.82 billion. The stock has returned 7.9% over the past month, outperforming the S&P 500's 1.9% gain.
Procter & Gamble, Amphenol, Vertiv Among Companies Set to Report Pre-Market Earnings on July 29, 2026
A slate of major companies including Procter & Gamble, Amphenol, and Vertiv Holdings are scheduled to report quarterly earnings before the market opens on July 29, 2026. Procter & Gamble is expected to post earnings per share of $1.41, a 4.73% decline from the prior year, while Amphenol's consensus forecast of $1.19 represents a 46.91% increase. Vertiv Holdings is projected to report $1.43 per share, up 50.53% year-over-year. Other notable reports include General Dynamics at $3.95, Automatic Data Processing at $2.59, Johnson Controls at $1.32, Aon at $3.77, Boston Scientific at $0.83, Cenovus Energy at $1.11, Entergy at $0.94, Old Dominion Freight Line at $1.52, and Garmin at $2.27. Zacks Investment Research provided forward price-to-earnings ratios for each company alongside industry comparisons.
Boston Scientific expects headcount reductions amid restructuring initiative
Boston Scientific is initiating a global restructuring programme that will result in job cuts across the business. The 2026 restructuring plan, agreed with the board on 21 July and disclosed in an SEC filing on 27 July, is expected to cost between $700m and $800m, with approximately $600m to $700m in future cash outlays, and aims to reduce annual pre-tax expenses by roughly $500m. The company estimates that up to $300m of the total cost will be incurred due to terminations, while up to $350m will relate to transferring product manufacturing lines between facilities and up to $150m for other costs. Boston Scientific shares rose 2.85% to $45.51 on 27 July and gained a further 2% at market open on 28 July.
J&J MedTech sales miss estimates as Abiomed weakness slows cardiovascular growth
Johnson & Johnson's MedTech segment posted second-quarter sales of $8.93 billion, up 4.5 percent but slightly below the Zacks Consensus Estimate of $8.96 billion, as slower cardiovascular performance weighed on results. Operational growth in the Cardiovascular business was 3.1 percent, held back by a 2 percent decline in Abiomed sales after a U.K. study prompted physicians to reassess use of the Impella heart pump, while Shockwave revenues rose 14.6 percent to $335 million and electrophysiology sales increased 3.1 percent amid competitive pulsed field ablation pressures. The other three MedTech businesses all accelerated, with Surgery up 3.9 percent, Orthopedics up 4.9 percent, and Vision up 6 percent. J&J tempered its Abiomed outlook, now expecting only modest growth in the second half of 2026, but remains optimistic about overall MedTech performance driven by strength in Vision, Orthopedics, Surgery, and new product launches including the recently approved OTTAVA robotic surgical system and the VARIPULSE pulsed field ablation system.
JNJ · Demand · Negative J&J MedTech sales missed estimates due to Abiomed weakness after a UK study reduced Impella use, and J&J tempered Abiomed outlook.
BSX · Competition · Negative Boston Scientific competes in electrophysiology; article notes competitive pulsed field ablation pressures, which may affect Boston Scientific's market share.
Ten S&P 500 Stocks Lost Over 40% in 2026 as Investors Dumped Everything AI Might Kill
Ten stocks in the S&P 500 lost more than 40% in 2026 even as the index rose 8.28%, as investors fled companies they believed artificial intelligence would disrupt. Intuit fell 55.27% after cheap AI tax tools emerged, prompting Goldman Sachs analyst Gabriela Borges to cut her price target to $276 from $519 and the company to reduce staff by 17% and lower its TurboTax forecast. Accenture dropped 45.21% as clients shifted spending to AI instead of consultants, with new orders slipping to $19.3 billion from $19.7 billion and the firm cutting its sales growth outlook to between 3% and 4%. Cognizant, Gartner, and The Trade Desk each lost between 44% and 55%, while the two worst performers fell for non-AI reasons: CoStar Group sank 58.86% after saying its Homes.com site would not cover costs until 2029, and Boston Scientific declined 53.59% after cutting its sales growth forecast and recalling Accolade pacemakers linked to four deaths and 2,557 serious injuries. Meanwhile, chip and memory makers surged, with Sandisk up 505.17%, Dell Technologies up 247.55%, and Micron Technology up 222.68%.
FDA warns against certain Boston Scientific percutaneous catheters after tip separation reports
The US FDA is recommending that certain lots of Boston Scientific's ENROUTE Transcarotid Neuroprotection System percutaneous catheters be avoided following reports of arterial sheath tip separation or partial tip separation. The company has reported one serious injury since July 9. The agency warned that tip separation may require endovascular or surgical retrieval of the retained tip, and complications can include embolism, stroke, transient ischemic attack, restenosis, or thrombosis.
BSX · Regulation · Negative FDA warns against certain lots of Boston Scientific's ENROUTE catheters due to tip separation risk, with one serious injury reported.
Robotic Endoscopy Devices Market to Reach $6.5 Billion by 2034
The global robotic endoscopy devices market is projected to grow from $2.8 billion in 2025 to $6.5 billion by 2034, at a compound annual growth rate of approximately 10%, according to a report by DelveInsight. North America accounted for about 42% of global revenue in 2025, driven by widespread adoption of robotic-assisted surgical technologies and the presence of major players such as Intuitive Surgical, Medtronic, and Johnson & Johnson MedTech. The therapeutic robotic endoscopes category was the largest product segment, while the Asia-Pacific region is expected to see the highest growth due to aging populations and rising investments in robotic surgery. Key companies in the market include Intuitive Surgical, Johnson & Johnson MedTech, Medtronic, Olympus, Boston Scientific, FUJIFILM, Stryker, KARL STORZ, Asensus Surgical, and CMR Surgical. Recent developments include FDA clearance of Medtronic's Hugo system for urologic procedures in December 2025 and FDA 510(k) clearance of CMR Surgical's Versius Plus system for cholecystectomy.
Robotics & Physical AI › Surgical & Medical Robotics ▲Demand
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
ISRG · Demand · Positive Market growth forecast and Intuitive Surgical's leading position in robotic endoscopy drive positive demand outlook.
CMR Surgical · Regulation · Positive FDA 510(k) clearance of CMR Surgical's Versius Plus system for cholecystectomy is a regulatory approval that enables market expansion.
MDT · Technology · Positive FDA clearance of Medtronic's Hugo system for urologic procedures is a positive regulatory milestone.
JNJ · Demand · Positive Johnson & Johnson MedTech is a major player in the growing robotic endoscopy market.
BSX · Demand · Positive Boston Scientific is a key company in the expanding robotic endoscopy market.
SYK · Demand · Positive Stryker is listed as a key player in the growing robotic endoscopy devices market.
Electrophysiology Market to Reach USD 43.05 Billion by 2035 at 12.79% CAGR
The global electrophysiology market is projected to grow from USD 12.89 billion in 2025 to USD 43.05 billion by 2035, at a compound annual growth rate of 12.79%, according to a new report by SNS Insider. Ablation catheters held the largest product segment share at 46.82% in 2025, while pulse field ablation is the fastest-growing segment with a CAGR of 17.64%. North America led the market with a 42.37% revenue share in 2025, and the Asia Pacific region is expected to grow the fastest at a 14.44% CAGR through 2035. Key companies include Abbott Laboratories, Medtronic, Johnson & Johnson MedTech, Boston Scientific, and Philips Healthcare.
USA
